Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells $221,370.40 in Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,540 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40. Following the transaction, the insider now owns 258,073 shares of the company’s stock, valued at $12,583,639.48. This represents a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.07, for a total value of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $59.12, for a total value of $394,034.80.
• On Wednesday, October 2nd, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $56.26, for a total value of $374,972.90.

Apogee Therapeutics Price Performance

Shares of APGE stock opened at $44.50 on Monday. The company has a market capitalization of $2.00 billion, a PE ratio of -18.39 and a beta of 2.30. The firm’s 50-day moving average is $51.43 and its two-hundred day moving average is $48.30. Apogee Therapeutics, Inc. has a 12 month low of $20.78 and a 12 month high of $72.29.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on APGE. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a report on Thursday. Finally, Wedbush boosted their target price on Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a report on Monday, December 2nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $83.88.

Hedge Funds Weigh In On Apogee Therapeutics

Large investors have recently modified their holdings of the business. Arizona State Retirement System lifted its stake in Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock worth $236,000 after purchasing an additional 258 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after acquiring an additional 285 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Apogee Therapeutics during the 3rd quarter valued at about $71,000. Principal Financial Group Inc. grew its position in Apogee Therapeutics by 26.3% in the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock valued at $253,000 after acquiring an additional 1,340 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its stake in Apogee Therapeutics by 25.7% during the third quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock worth $517,000 after purchasing an additional 1,800 shares during the period. Institutional investors and hedge funds own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.